Malignant neoplasm of lung
J&J combo signals new era in EGFR lung cancer with survival win against AstraZeneca’s Tagrisso
Continuance of life, Combined, Epidermal Growth Factor Receptor, Malignant neoplasm of lung, Overall Survival, Tagrisso
J&J’s Rybrevant Combination Therapy Outperforms AstraZeneca’s Tagrisso in Lung Cancer Survival Trial
J&J, Rybrevant, AstraZeneca, Tagrisso, lung cancer, NSCLC, survival trial, combination therapy
AstraZeneca’s Tagrisso Expands EU Approval for NSCLC Treatment
AstraZeneca, Tagrisso, NSCLC, EU approval, EGFR mutations, lung cancer treatment
FDA Approves Ensartinib for First-Line Treatment of ALK-Positive NSCLC
Ensartinib, ALK-positive NSCLC, FDA approval, lung cancer treatment, Xcovery Holdings
FDA Rejects Subcutaneous Version of J&J’s Lung Cancer Drug Rybrevant Due to Manufacturing Concerns
FDA rejection, J&J, Subcutaneous Rybrevant, Manufacturing issues, Lung cancer drug, Non-small cell lung cancer (NSCLC), Epidermal growth factor receptor (EGFR) mutations
FDA Grants Accelerated Approval to Merus’ Bizengri for NRG1+ Lung and Pancreatic Cancers
Bizengri, NRG1+ cancers, FDA accelerated approval, lung cancer, pancreatic cancer, zenocutuzumab-zbco, Merus N.V.
Roche’s TIGIT Drug Candidate Tiragolumab Fails to Meet Overall Survival Endpoint in Phase 3 Lung Cancer Trial
Roche, TIGIT, tiragolumab, lung cancer, phase 3 trial, SKYSCRAPER-01, overall survival, Keytruda, Tecentriq
FDA Delays Decision on Merus’ Zenocutuzumab for NRG1+ Lung and Pancreatic Cancer
Zenocutuzumab, NRG1+ cancer, FDA delay, Merus, lung cancer, pancreatic cancer, bispecific antibody.
PrognomiQ Secures $34 Million Funding to Enhance Early Lung Cancer Detection with Multi-Omics Technology
PrognomiQ, lung cancer detection, multi-omics technology, early detection test, funding, series D round
Novocure’s Optune Lua Wins FDA Approval for Metastatic Non-Small Cell Lung Cancer Treatment
Novocure, Optune Lua, FDA approval, metastatic non-small cell lung cancer, TTFields, lung cancer treatment, PD-1/PD-L1 inhibitors, docetaxel.